BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD.

BrightGene Bio-Medical Technology Co., Ltd.

688166

CNE100003PR1

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-28 pm EDT			5-day change	1st Jan Change
30.71 ^CNY	+3.82%		+19.12%	-12.26%

Apr. 27	BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 02	Tranche Update on BrightGene Bio-Medical Technology Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.	CI

Tranche Update on BrightGene Bio-Medical Technology Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.

April 01, 2024

From February 6, 2024 to March 31, 2024, the company has repurchased 99,900 shares, representing 0.02% for CNY 2.94 million. With this, the company has completed the repurchase of 99,900 shares, representing 0.02% for CNY 2.94 million under the buyback announced on February 7, 2024.

Latest news about BrightGene Bio-Medical Technology Co., Ltd.

BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 27	CI
Tranche Update on BrightGene Bio-Medical Technology Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.	Apr. 01	CI
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 25	CI
BrightGene Bio-Medical Technology Co., Ltd. announces an Equity Buyback for CNY 20 million worth of its shares.	Feb. 06	CI
BrightGene Bio-Medical Technology Co., Ltd. authorizes a Buyback Plan.	Feb. 05	CI
Oralead Pharma announced that it has received funding from HighLight Capital, Shenzhen Qianhai BangQin Investment Co., Ltd., BrightGene Bio-Medical Technology Co., Ltd., Shenyang Borui Pharmaceutical Co., Ltd.	Jan. 28	CI
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Chinese Regulator Issues Warning Against BrightGene Bio-Medical Chairman Over Weight Loss Claims	23-10-18	MT
Kanghui Pharma Denies Speculations of Unit’s Involvement in Production of Weight-Loss Drugs	23-10-17	MT
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-18	CI
BrightGene Bio-Medical Technology's Unit Gets Hospital's Approval for Diabetes Drug Trial	23-07-27	MT
Chinese Drug Regulator Certifies Two Drugs of BrightGene's Unit	23-07-06	MT
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-24	CI
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
BrightGene Bio-Medical to Hike Investment in API Production Project to 500 Million Yuan	23-02-08	MT
Xinchuang Biomedical Technology Subsidiary Gets Nod to Hold Anti-Diabetes Drug Trial	22-12-30	MT
BrightGene Bio-Medical Technology Co., Ltd. announced that it has received CNY 226.613082 million in funding from Horizon Asset Management Co. Ltd., Shanghai Leitu Asset Management Co., Ltd. and other investors	22-11-20	CI
BrightGene Bio-Medical Technology Unit Gets Regulatory Approval For Anti-Inflammatory Drug Ingredient	22-11-18	MT
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-24	CI
BrightGene Bio-Medical Technology Co., Ltd.(SHSE:688166) dropped from Shanghai Stock Exchange Health Care Sector Index	22-06-10	CI
Suzhou Hongbo Venture Capital Partnership agreed to acquire 2.42% stake in Caike Biotechnology Co., Ltd. from BrightGene Bio-Medical Technology Co., Ltd. for CNY 20 million.	22-06-08	CI
BrightGene Bio-Medical Technology Co., Ltd. announced that it expects to receive CNY 222.3054 million in funding	22-06-06	CI
Bonuo Kangyuan Pharmaceutical Technology Co., Ltd intends to acquire 49% interest in Boze Gelin Pharmaceutical Co Ltd. from BrightGene Bio-Medical Technology Co., Ltd..	22-05-31	CI
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI

Chart BrightGene Bio-Medical Technology Co., Ltd.

Duration

Period

Chart BrightGene Bio-Medical Technology Co., Ltd.

More charts

Company Profile

BrightGene Bio-Medical Technology Co Ltd is a China-based company mainly engaged in the research, development and production of generic drugs and original new drugs. The Company's main products include antifungal active pharmaceutical ingredients (APIs), antiviral APIs, immunosuppressive APIs, and other APIs and preparations. The Company's generic drugs mainly include entecavir, caspofungin, micafungin, posaconazole, everolimus and fondaparinux sodium. The Company mainly conducts its businesses in domestic and overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-21 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD.	-12.26%	1.79B
ELI LILLY AND COMPANY	+26.47%	664B
NOVO NORDISK A/S	+28.13%	567B
JOHNSON & JOHNSON	-6.33%	354B
MERCK & CO., INC.	+19.35%	330B
ABBVIE INC.	+4.23%	286B
ASTRAZENECA PLC	+13.57%	234B
NOVARTIS AG	+4.81%	199B
ROCHE HOLDING AG	-10.22%	196B
AMGEN INC.	-4.04%	148B

Other Pharmaceuticals

BrightGene Bio-Medical Technology Co., Ltd.

Equities

688166

CNE100003PR1

Pharmaceuticals

Tranche Update on BrightGene Bio-Medical Technology Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.

Latest news about BrightGene Bio-Medical Technology Co., Ltd.

Chart BrightGene Bio-Medical Technology Co., Ltd.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Pharmaceuticals